Ratings AMOREPACIFIC Group

Equities

A002790

KR7002790004

End-of-day quote Korea S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
31,450 ^KRW	+4.83%		+5.71%	+7.52%

Mar. 07	AMOREPACIFIC Group Reports Earnings Results for the Full Year Ended December 31, 2023	CI
Jan. 31	Amorepacific's Net Income Jumps 55.5% in Q4; Shares Decline 10%	MT

Summary

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

The earnings growth currently anticipated by analysts for the coming years is particularly strong.
The stock, which is currently worth 2024 to 590.07 times its sales, is clearly overvalued in comparison with peers.
The company appears to be poorly valued given its net asset value.
The company has a low valuation given the cash flows generated by its activity.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
The average consensus view of analysts covering the stock has deteriorated over the past four months.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Personal Products

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
AMOREPACIFIC GROUP	+7.52%	1.85B		B+
KAO CORPORATION	+10.09%	18.86B		B+
GALDERMA GROUP AG	0.00%	17.37B	-	-
SHISEIDO COMPANY, LIMITED	-1.32%	10.65B		A-
COTY INC.	-7.37%	10.26B		A-
AMOREPACIFIC CORPORATION	+3.86%	6.72B		B+
PROYA COSMETICS CO.,LTD.	+9.76%	5.94B		B
NATURA &CO HOLDING S.A.	-1.42%	4.55B		B+
INTER PARFUMS, INC.	-16.67%	3.83B		C-
INTERPARFUMS	-3.97%	3.48B		B-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes